Lifecore Biomedical, Inc.
LFCR
$6.18
$0.030.49%
| 11/24/2024 | 08/25/2024 | 05/26/2024 | 02/25/2024 | 11/26/2023 | |
|---|---|---|---|---|---|
| Revenue | 16.47% | 23.42% | 24.20% | 30.31% | 7.91% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.47% | 23.42% | 24.20% | 30.31% | 7.91% |
| Cost of Revenue | 2.26% | 5.80% | 14.78% | 35.89% | 15.50% |
| Gross Profit | 57.30% | 79.95% | 49.55% | 17.07% | -9.22% |
| SG&A Expenses | 13.38% | 12.05% | 0.73% | 21.84% | 9.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.35% | 7.27% | 9.15% | 28.50% | 12.73% |
| Operating Income | 59.27% | 66.46% | 69.69% | -15.86% | -52.18% |
| Income Before Tax | 67.82% | 108.29% | 114.88% | 34.86% | -76.07% |
| Income Tax Expenses | -44.89% | -82.14% | -40.58% | 2.62% | 7.31% |
| Earnings from Continuing Operations | 67.66% | 108.14% | 114.53% | 34.31% | -75.29% |
| Earnings from Discontinued Operations | 103.32% | 102.83% | 107.59% | 100.46% | 61.06% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 80.30% | 106.58% | 112.07% | 82.58% | 21.77% |
| EBIT | 59.27% | 66.46% | 69.69% | -15.86% | -52.18% |
| EBITDA | 101.46% | 100.79% | 127.58% | -499.41% | -190.38% |
| EPS Basic | 79.18% | 106.73% | 111.90% | 82.59% | 23.50% |
| Normalized Basic EPS | 48.94% | 124.05% | 131.90% | 120.69% | 5.14% |
| EPS Diluted | 76.05% | 101.53% | 106.85% | 78.30% | 21.18% |
| Normalized Diluted EPS | 42.18% | 112.23% | 119.06% | 102.35% | -6.64% |
| Average Basic Shares Outstanding | 4.23% | 1.70% | 2.03% | 1.91% | 2.47% |
| Average Diluted Shares Outstanding | 4.16% | 11.75% | 12.14% | 12.06% | 7.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
